Cytokinetics, Incorporated(CYTK) Stock Research - Grey Stern Research

Cytokinetics, Incorporated (CYTK) Stock Analysis

$46.87 (3.63%)

CYTK Financial Performance


Use the table below to view Cytokinetics, Incorporated's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $46.87 -
52 Week Low $44.49 -
52 Week High $86.63 -
Market Cap $5.5 Billion 4/16
Gross Margin 100% 1/16
Profit Margin -100% 15/16
EBITDA margin -29859% 16/16
Q3 - 2024 Revenue $463,000 5/16
Q3 - 2024 Earnings -$160.5 Million 16/16
Q3 - 2024 Free Cash Flow -$104.0 Million 13/16
Trailing 4 Quarters Revenue $3.2 Million 7/16
Trailing 4 Quarters Earnings -$576.4 Million 16/16
Quarterly Earnings Growth -24% 8/16
Annual Earnings Growth -12% 7/16
Quarterly Revenue Growth 22% 4/16
Annual Revenue Growth 8% 4/16
Cash On Hand $46.9 Million 12/16
Short Term Debt $30.4 Million 2/16
Long Term Debt $759.3 Million 1/16

Cytokinetics, Incorporated Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Cytokinetics, Incorporated's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/16
PS 1718.33 2/16
PB 0.00 16/16
PC 117.97 1/16
Liabilities to Equity 0.00 16/16
ROA -0.40 13/16
ROE 41.43 1/16
Current Ratio 0.99 16/16
Quick Ratio 0.70 15/16
Long Term Debt to Equity -54.58 16/16
Debt to Equity -48.51 16/16
Burn Rate 0.24 15/16
Cash to Cap 0.01 14/16
CCR 0.65 13/16
EV to EBITDA -44.55 14/16
EV to Revenue 1913.42 2/16

Company Details

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CEO: Mr. Robert Blum

Website: https://www.cytokinetics.com

Address: 280 E Grand Ave South San Francisco, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Cytokinetics, Incorporated Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Cytokinetics, Incorporated. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Dyne Therapeutics, Inc. DYN $1.6 Billion
Blueprint Medicines Corporation BPMC $6.7 Billion
Arvinas, Inc. ARVN $1.2 Billion
Karuna Therapeutics, Inc. KRTX $12.6 Billion
Stoke Therapeutics, Inc. STOK $502.7 Million
X4 Pharmaceuticals, Inc. XFOR $78.6 Million
Revolution Medicines, Inc. RVMD $7.3 Billion
Black Diamond Therapeutics, Inc. BDTX $119.4 Million
Pliant Therapeutics, Inc. PLRX $768.6 Million
Relay Therapeutics, Inc. RLAY $637.7 Million
Inozyme Pharma, Inc. INZY $88.7 Million
Edgewise Therapeutics, Inc. EWTX $2.7 Billion
Terns Pharmaceuticals, Inc. TERN $393.3 Million
DICE Therapeutics, Inc. DICE $2.3 Billion
Acumen Pharmaceuticals, Inc. ABOS $102.7 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
CYTK Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 463,000 -$160.5 Million
Q2 2024 $ 249,000 -$143.3 Million
Q1 2024 $ 835,000 -$135.6 Million
Q4 2023 $ 1.7 Million -$136.9 Million
Q3 2023 $ 378,000 -$129.4 Million
Q2 2023 $ 867,000 -$128.6 Million
Q1 2023 $ 4.6 Million -$129.4 Million
Q4 2022 $ 2.0 Million -$131.5 Million

View All

CYTK Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $46.9 Million $1.4 Billion $674.9 Million -$13.9 Million
Q2 2024 $190.5 Million $1.5 Billion $790.2 Million $108.6 Million
Q1 2024 $120.4 Million $808.1 Million $754.9 Million -$396.2 Million
Q4 2023 $113.4 Million $824.3 Million $755.8 Million -$386.3 Million
Q3 2023 $99.7 Million $740.6 Million $748.5 Million -$438.8 Million
Q2 2023 $68.6 Million $779.9 Million $749.3 Million -$333.1 Million
Q1 2023 $101.6 Million $889.8 Million $750.2 Million -$229.0 Million
Q4 2022 $65.6 Million $1.0 Billion $749.3 Million -$107.9 Million

View All

CYTK Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$104.0 Million -$2.5 Million -$143.3 Million
Q2 2024 -$101.2 Million -$1.9 Million $70.2 Million
Q1 2024 -$127.8 Million $1.8 Million $7.0 Million
Q4 2023 -$74.1 Million -$77,000 $13.3 Million
Q3 2023 $29,000 $0 $29,000
Q2 2023 $27,000 $0 $27,000
Q1 2023 -$122.7 Million -$402,000 $36.0 Million
Q4 2022 -$101.4 Million -$3.2 Million -$39.1 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions